SCHEMBL9824985

SCHEMBL9824985

NC(=O)CN1CCC(CCN2CCCCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
POLB P06746 2/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
SIRT3 Q9NTG7 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ACHE P22303 1/20 0.40
HTR4 Q13639 1/20 0.40
MAPT P10636 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
CYP1A2 P05177 2/20 0.39
CACNA1I Q9P0X4 1/20 0.38
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
TP53 P04637 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9825263 0.90 L3MBTL1 (0.47) L3MBTL1POLBPKMTSHRKDM4E
SCHEMBL9824090 0.89 L3MBTL1 (0.46) L3MBTL1POLBPKMTSHRKDM4E
SCHEMBL22006816 0.85 HTT (0.47) L3MBTL1POLBPKMTSHRKDM4E
SCHEMBL22266281 0.84 SIGMAR1 (0.41) POLBPKMTSHRKDM4EACHE
SCHEMBL22266184 0.83 CHRM5 (0.53) L3MBTL1POLBPKMTSHRSIRT2
SCHEMBL1031783 0.80 KDM4E (0.60) L3MBTL1POLBPKMTSHRKDM4E
SCHEMBL63826 0.80 KDM4E (0.60) L3MBTL1POLBPKMTSHRKDM4E
SCHEMBL7484330 0.79 L3MBTL1 (0.44) L3MBTL1POLBSIRT2SIRT1SIRT3
SCHEMBL7113024 0.79 POLB (0.47) L3MBTL1POLBPKMTSHRKDM4E
SCHEMBL6174155 0.78 KDM4E (0.59) L3MBTL1POLBPKMTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 US disclosed
EP-0273239-B1 CONDENSED DIAZEPINONES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM Dr. Karl Thomae GmbH (DE) 1991-03-06 EP disclosed
US-4873236-A BRADYCARDIAL AGENTS DR. KARL THOMAE GMBH (DE) 1989-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL L3MBTL1 887/4885POLB 3156/4885PKM 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.